NuProbe Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$50M
- Investors
-
22
NuProbe General Information
Description
Developer of precision diagnostic technology designed to offer early detection of cancer and infectious diseases. The company's technology offers precise and comprehensive capturing of disease signatures for cancer research and pharmaceutical applications with high sensitivity and multiplexing capability to detect difficult DNA biomarkers like CNVs, gene fusions, and low-frequency mutation, enabling doctors and healthcare specialists to act early and treat the patient's illness
Contact Information
Website
www.nuprobe.comCorporate Office
- 2575 West Bellfort Avenue
- Suite 200
- Houston, TX 77054
- United States
Corporate Office
- 2575 West Bellfort Avenue
- Suite 200
- Houston, TX 77054
- United States
NuProbe Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 02-Jun-2022 | $50M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 11-Jan-2021 | Completed | Generating Revenue | |||
| 5. Grant | 31-Dec-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 08-Jan-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 23-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 1. Grant | 01-Jan-2018 | $749K | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NuProbe Comparisons
Industry
Financing
Details
NuProbe Competitors (41)
One of NuProbe’s 41 competitors is GRAIL, a Formerly VC-backed company based in Menlo Park, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GRAIL | Formerly VC-backed | Menlo Park, CA | ||||
| Recombinetics | Venture Capital-Backed | Eagan, MN | ||||
| Menarini Silicon Biosystems | Formerly VC-backed | Castel Maggiore, Italy | ||||
| ROCA Test | Formerly VC-backed | Cambridge, United Kingdom | ||||
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China |
NuProbe Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NuProbe Patents
NuProbe Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250011833-A1 | Methods and compositions for sequencing and fusion detection using randomer reverse primers | Pending | 09-Nov-2021 | ||
| US-20220298564-A1 | High sensitivity detection of microsatellite loci by blocker displacement amplification with multiple blockers and its use in microsatellite instability detection | Inactive | 16-Mar-2021 | ||
| EP-4308725-A1 | High sensitivity detection of microsatellite loci by blocker displacement amplification with multiple blockers and its use in microsatellite instability detection | Inactive | 16-Mar-2021 | ||
| EP-4278009-A1 | Cycle multiplexing for highly multiplexed quantitative pcr | Inactive | 15-Jan-2021 | ||
| US-20230399687-A1 | Quantitative multiplex amplicon sequencing system | Inactive | 02-Nov-2020 | C12Q1/6858 |
NuProbe Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NuProbe Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AstraZeneca | Corporation | Minority | ||
| China Resources Capital Management | Corporate Venture Capital | Minority | ||
| Deguan Capital | Asset Manager | Minority | ||
| Haoreng Capital | Venture Capital | Minority | ||
| Pappas Capital | Venture Capital | Minority |
NuProbe Acquisitions (1)
NuProbe’s most recent deal was a Merger/Acquisition with Carrier Gene. The deal was made on 06-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carrier Gene | 06-Jan-2020 | Merger/Acquisition | Clinics/Outpatient Services |
NuProbe FAQs
-
When was NuProbe founded?
NuProbe was founded in 2016.
-
Where is NuProbe headquartered?
NuProbe is headquartered in Houston, TX.
-
What is the size of NuProbe?
NuProbe has 29 total employees.
-
What industry is NuProbe in?
NuProbe’s primary industry is Biotechnology.
-
Is NuProbe a private or public company?
NuProbe is a Private company.
-
What is NuProbe’s current revenue?
The current revenue for NuProbe is .
-
How much funding has NuProbe raised over time?
NuProbe has raised $111M.
-
Who are NuProbe’s investors?
AstraZeneca, China Resources Capital Management, Deguan Capital, Haoreng Capital, and Pappas Capital are 5 of 22 investors who have invested in NuProbe.
-
Who are NuProbe’s competitors?
GRAIL, Recombinetics, Menarini Silicon Biosystems, ROCA Test, and GeneCast Biotechnology are some of the 41 competitors of NuProbe.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
